Myelomatosis therapy trial for patients of all age groups.

Trial Profile

Myelomatosis therapy trial for patients of all age groups.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2015

At a glance

  • Drugs Thalidomide (Primary) ; Thalidomide (Primary) ; Antineoplastics; Clodronic acid; Cyclophosphamide; Dexamethasone; Doxorubicin; Melphalan; Prednisolone; Prednisone; Vincristine; Zoledronic acid
  • Indications Graft-versus-host disease; Multiple myeloma; Osteolysis
  • Focus Therapeutic Use
  • Acronyms MRC-Myeloma-IX; Myeloma-IX
  • Most Recent Events

    • 16 Jan 2014 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network
    • 10 Dec 2012 Results of thalidomide maintenance according to biological risk groups presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 17 Jun 2012 Long-term follow-up results for the zolendronic acid versus clodronic acid randomisation presented at the 17th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top